• A1 and AMD3100 in Colorectal Cancer Research

  2026-08-16

  Khorramdelazad and colleagues evaluated A1, a fluorinated CXCR4 inhibitor, against AMD3100 across computational, cellular, and mouse colorectal cancer models. A1 showed stronger predicted CXCR4 binding, inhibited CT-26 proliferation and migration, and produced greater effects on tumor growth and immunosuppressive signaling than AMD3100, while remaining a preclinical candidate requiring further validation.

• PBA-Modified PAD4 Inhibitors Block NET-Driven Tumors

  2026-08-15

  The reference study developed phenylboronic acid-modified PAD4 inhibitors that preferentially interact with tumor cells while suppressing the PAD4–H3cit–NET pathway in neutrophils. Compound 5i reduced tumor growth and lung metastasis in mouse models, illustrating how tumor-directed delivery may improve the therapeutic window of PAD4 inhibition.

• Oligo (dT) 25 Beads for mRNA Workflows

  2026-08-14

  Oligo (dT) 25 Beads provide a rapid, selective route to intact polyadenylated transcripts from eukaryotic RNA, cells, or tissues. This guide translates immune-aging findings into practical mRNA capture, cDNA, RT-PCR, and sequencing workflows while emphasizing assay limits and troubleshooting.

• Carbapenemase Gene Transmission in CREC, Guangdong

  2026-08-14

  This 2025 multicenter study combined gene-location analysis, antimicrobial susceptibility testing, conjugation experiments, mobile-element screening, and strain typing to clarify how carbapenemase-encoding genes circulate in carbapenem-resistant Enterobacter cloacae. Its findings identify plasmid-associated blaNDM-1 and frequent transfer potential as central concerns for surveillance and infection-control research.

• Trelagliptin Restores PI-3K/AKT Signaling in Adipocytes

  2026-08-13

  The reference study investigates how trelagliptin succinate, beyond its established DPP-4 inhibition, improves insulin resistance in differentiated 3T3-L1 adipocytes. Its key contribution is the linking of improved glucose intake and GLUT4 membrane localization with increased IRS-1/AKT signaling and reduced free fatty acid and resistin secretion.

• JDJM Modulates Wnt/β-Catenin Signaling in Knee OA

  2026-08-13

  The reference study connects the anti-inflammatory effects of Jiawei Duhuo Jisheng mixture (JDJM) with suppression of Wnt/β-catenin signaling in osteoarthritic synovium. By combining rabbit synovial fibroblast experiments with a rabbit knee osteoarthritis model, it provides mechanistic evidence that synovial pathway activity may be a tractable complement to cartilage-centered research.

• Flumequine: From Target Inhibition to Cell Response

  2026-08-12

  Flumequine is a DNA topoisomerase II inhibitor suited to mechanistic studies that connect enzyme inhibition with cellular drug response. This evidence-guided article explains how to interpret its reported IC50 without confusing growth arrest, cell killing, or assay-specific effects.

• Beijing 2023 Mycoplasma pneumoniae Resistance Study

  2026-08-12

  A 2024 study of pediatric Mycoplasma pneumoniae isolates from Beijing found complete in vitro resistance to erythromycin and azithromycin, together with a universal A2063G resistance mutation and higher azithromycin MICs in 2023. The work integrates susceptibility testing, molecular typing, and clinical characterization, providing a focused framework for bacterial infection research and antibacterial drug resistance surveillance.

• WRN Inhibition and p53/PUMA Synthetic Lethality in MSI CRC

  2026-08-11

  This PNAS study identifies p53/PUMA-mediated apoptosis as the mechanism linking Werner helicase loss to synthetic lethality in mismatch repair-deficient colorectal cancer. Its genetic, pharmacologic, and xenograft evidence supports WRN targeting in p53-wildtype MSI tumors while also highlighting the need to distinguish WRN-specific effects from broader RecQ helicase inhibition.

• Boc-D-FMK: Practical Pan-Caspase Workflows

  2026-08-11

  Boc-D-FMK provides a cell-permeable, irreversible way to test whether caspase activation drives apoptosis and inflammatory signaling. This guide translates its use into reproducible cell and animal workflows, with assay controls, model-specific applications, and troubleshooting for renal endothelial and hepatocyte studies.

• Luminescent ATP Cell Viability Assay Kit for GBM

  2026-08-10

  The Luminescent ATP Cell Viability Assay Kit I converts intracellular ATP into a rapid, sensitive luminescent readout for glioblastoma proliferation, peptide-delivery, and drug-response studies. Its broad 10–30,000-cell linear range and approximately 10-minute detection window support efficient cytotoxicity assay optimization without a separate lysis step.

• Patient-Derived Gastric Cancer Assembloids

  2026-08-09

  A 2025 Cancers study developed patient-derived gastric cancer assembloids by combining matched tumor organoids with tumor-derived stromal subpopulations. The model reproduced clinically relevant epithelial–stromal interactions, altered transcriptional states and drug responses, and provides a stronger framework for resistance studies and personalized screening than organoid monocultures alone.

• PTEN mRNA: From Mechanism to Translation

  2026-08-08

  PTEN restoration is emerging as a strategic mRNA approach for reconnecting tumor suppression with antitumor immunity. This thought-leadership article examines the PI3K/Akt signaling pathway, Cap 1 and poly(A) design, delivery validation, and translational priorities for researchers using EZ Cap™ Human PTEN mRNA in cancer research and gene therapy research.

• Eicosapentaenoic Acid (EPA): Research Guide

  2026-08-07

  Eicosapentaenoic Acid is an EPA omega-3 fatty acid used in mechanistic cardiovascular disease research. Product data describe membrane-lipid modulation, endothelial cell migration inhibition, lipid oxidation effects, and prostaglandin I2 enhancement, while the supplied reference study supports an arachidonic-acid immune mechanism rather than an EPA clinical conclusion.

• Cabozantinib (XL184) in RCC: Advanced Workflows and Troubles

  2026-08-07

  Cabozantinib (XL184) is revolutionizing renal cell carcinoma research by enabling timescale-dependent phosphoproteomic profiling and robust antiangiogenic assays. This article translates recent systems-level findings into practical protocol enhancements, troubleshooting strategies, and actionable tips for maximizing reproducibility and insight.

15432 records 1/1029 page Next 12345 下5页 Last page